Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2023

Open Access 01-12-2023 | Sulfonylurea | Case Report

De novo HNF1A mutation of young maturity-onset diabetes 3 of a young girl—Case report

Authors: Haoran Peng, Jianbo Li, Zhang Wang

Published in: BMC Endocrine Disorders | Issue 1/2023

Login to get access

Abstract

Young maturity-onset diabetes of the young type3(MODY3) as a special type of diabetes, the probability of diagnosis is low. This article reports on a case and reviews the relevant knowledge of the disease. We report an 11-year-and-11-month-old girl whose grandmother died from diabetic complications while the rest of the families were non-diabetes. The proband was initially treated with insulin and metformin but the threatment proved inefficient. After an exome-targeted capture sequencing test, she was diagnosed with mature-onset diabetes of young type 3 (MODY3), and sulfonylureas make sense. The key to mody treatment is a correct and timely diagnosis, which contributes to helping patients overcome the problems of MODY3, especially for blood sugar control.
Literature
1.
go back to reference Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia. 2010;53:2504–8.CrossRefPubMed Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia. 2010;53:2504–8.CrossRefPubMed
2.
go back to reference C TPAJEPM, Aj BM. B, Maturity onset diabetes of the young due to HNF1A variants in Croatia. Biochem Medica. 2018;28.020703 C TPAJEPM, Aj BM. B, Maturity onset diabetes of the young due to HNF1A variants in Croatia. Biochem Medica. 2018;28.020703
3.
go back to reference Shields B, Colclough K. Towards a systematic nationwide screening strategy for MODY. Diabetologia. 2017;60:609–12.CrossRefPubMed Shields B, Colclough K. Towards a systematic nationwide screening strategy for MODY. Diabetologia. 2017;60:609–12.CrossRefPubMed
4.
go back to reference Sahoo SK, Zaidi G, Vipin VP, Chapla A, Thomas N, Yu L, et al. Heterogeneity in the aetiology of diabetes mellitus in young adults: a prospective study from north India. Indian J Med Res. 2019;149:479–88.CrossRefPubMedPubMedCentral Sahoo SK, Zaidi G, Vipin VP, Chapla A, Thomas N, Yu L, et al. Heterogeneity in the aetiology of diabetes mellitus in young adults: a prospective study from north India. Indian J Med Res. 2019;149:479–88.CrossRefPubMedPubMedCentral
5.
go back to reference Radha V, Ek J, Anuradha S, Hansen T, Pedersen O, Mohan V. Identification of novel variants in the hepatocyte nuclear factor-1alpha gene in south indian patients with maturity onset diabetes of young. J Clin Endocrinol Metab. 2009;94:1959–65.CrossRefPubMed Radha V, Ek J, Anuradha S, Hansen T, Pedersen O, Mohan V. Identification of novel variants in the hepatocyte nuclear factor-1alpha gene in south indian patients with maturity onset diabetes of young. J Clin Endocrinol Metab. 2009;94:1959–65.CrossRefPubMed
6.
go back to reference Wang X, Wang T, Yu M, Zhang H, Ping F, Zhang Q, et al. Screening of HNF1A and HNF4A mutation and clinical phenotype analysis in a large cohort of chinese patients with maturity-onset diabetes of the young. Acta Diabetol. 2019;56:281–8.CrossRefPubMed Wang X, Wang T, Yu M, Zhang H, Ping F, Zhang Q, et al. Screening of HNF1A and HNF4A mutation and clinical phenotype analysis in a large cohort of chinese patients with maturity-onset diabetes of the young. Acta Diabetol. 2019;56:281–8.CrossRefPubMed
7.
go back to reference Balamurugan K, Bjørkhaug L, Mahajan S, Kanthimathi S, Njølstad PR, Srinivasan N, et al. Structure-function studies of HNF1A (MODY3) gene mutations in south indian patients with monogenic diabetes. Clin Genet. 2016;90:486–95.CrossRefPubMed Balamurugan K, Bjørkhaug L, Mahajan S, Kanthimathi S, Njølstad PR, Srinivasan N, et al. Structure-function studies of HNF1A (MODY3) gene mutations in south indian patients with monogenic diabetes. Clin Genet. 2016;90:486–95.CrossRefPubMed
8.
go back to reference Pihoker C, Gilliam LK, Ellard S, Dabelea D, Davis C, Dolan LM, et al. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for diabetes in Youth. J Clin Endocrinol Metab. 2013;98:4055–62.CrossRefPubMedPubMedCentral Pihoker C, Gilliam LK, Ellard S, Dabelea D, Davis C, Dolan LM, et al. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for diabetes in Youth. J Clin Endocrinol Metab. 2013;98:4055–62.CrossRefPubMedPubMedCentral
9.
go back to reference Colclough K, Bellanne-Chantelot C, Saint-Martin C, Flanagan SE, Ellard S. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha and 4 alpha in maturity-onset diabetes of the young and hyperinsulinemic hypoglycemia. Hum Mutat. 2013;34:669–85.CrossRefPubMed Colclough K, Bellanne-Chantelot C, Saint-Martin C, Flanagan SE, Ellard S. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha and 4 alpha in maturity-onset diabetes of the young and hyperinsulinemic hypoglycemia. Hum Mutat. 2013;34:669–85.CrossRefPubMed
10.
go back to reference Dusatkova P, Pruhova S, Sumnik Z, Kolouskova S, Obermannova B, Cinek O, et al. HNF1A mutation presenting with fetal macrosomia and hypoglycemia in childhood prior to onset of overt diabetes. J Pediatr Endocrinol Metab JPEM. 2011;24:187–9.CrossRefPubMed Dusatkova P, Pruhova S, Sumnik Z, Kolouskova S, Obermannova B, Cinek O, et al. HNF1A mutation presenting with fetal macrosomia and hypoglycemia in childhood prior to onset of overt diabetes. J Pediatr Endocrinol Metab JPEM. 2011;24:187–9.CrossRefPubMed
11.
go back to reference Valkovicova T, Skopkova M, Stanik J, Gasperikova D. Novel insights into genetics and clinics of the HNF1A-MODY. Endocr Regul. 2019;53:110–34.CrossRefPubMed Valkovicova T, Skopkova M, Stanik J, Gasperikova D. Novel insights into genetics and clinics of the HNF1A-MODY. Endocr Regul. 2019;53:110–34.CrossRefPubMed
12.
go back to reference Jy X, Qh D, Nm VC, Sc WST. Genetic and clinical characteristics of maturity-onset diabetes of the young in chinese patients. Eur J Hum Genet EJHG. 2005;13:422–7.CrossRef Jy X, Qh D, Nm VC, Sc WST. Genetic and clinical characteristics of maturity-onset diabetes of the young in chinese patients. Eur J Hum Genet EJHG. 2005;13:422–7.CrossRef
13.
go back to reference Romuld IB, Kalleklev T-L, Molnes J, Juliusson PB, Njølstad PR, Sagen JV. Impact of overweight on glucose homeostasis in MODY2 and MODY3. Diabet Med J Br Diabet Assoc. 2021;38:e14649.CrossRef Romuld IB, Kalleklev T-L, Molnes J, Juliusson PB, Njølstad PR, Sagen JV. Impact of overweight on glucose homeostasis in MODY2 and MODY3. Diabet Med J Br Diabet Assoc. 2021;38:e14649.CrossRef
14.
go back to reference Kropff J, Selwood MP, McCarthy MI, Farmer AJ, Owen KR. Prevalence of monogenic diabetes in young adults: a community-based, cross-sectional study in Oxfordshire, UK. Diabetologia. 2011;54:1261–3.CrossRefPubMed Kropff J, Selwood MP, McCarthy MI, Farmer AJ, Owen KR. Prevalence of monogenic diabetes in young adults: a community-based, cross-sectional study in Oxfordshire, UK. Diabetologia. 2011;54:1261–3.CrossRefPubMed
15.
go back to reference Fu J, Wang T, Liu J, Wang X, Zhang Q, Li M, et al. Using clinical indices to Distinguish MODY2 (GCK mutation) and MODY3 (HNF1A mutation) from type 1 diabetes in a Young Chinese Population. Diabetes Ther Res Treat Educ Diabetes Relat Disord. 2019;10:1381–90. Fu J, Wang T, Liu J, Wang X, Zhang Q, Li M, et al. Using clinical indices to Distinguish MODY2 (GCK mutation) and MODY3 (HNF1A mutation) from type 1 diabetes in a Young Chinese Population. Diabetes Ther Res Treat Educ Diabetes Relat Disord. 2019;10:1381–90.
16.
go back to reference Mughal SA, Park R, Nowak N, Gloyn AL, Karpe F, Matile H, et al. Apolipoprotein M can discriminate HNF1A-MODY from type 1 diabetes. Diabet Med J Br Diabet Assoc. 2013;30:246–50.CrossRef Mughal SA, Park R, Nowak N, Gloyn AL, Karpe F, Matile H, et al. Apolipoprotein M can discriminate HNF1A-MODY from type 1 diabetes. Diabet Med J Br Diabet Assoc. 2013;30:246–50.CrossRef
17.
go back to reference McDonald TJ, McEneny J, Pearson ER, Thanabalasingham G, Szopa M, Shields BM, et al. Lipoprotein composition in HNF1A-MODY: differentiating between HNF1A-MODY and type 2 diabetes. Clin Chim Acta Int J Clin Chem. 2012;413:927–32.CrossRef McDonald TJ, McEneny J, Pearson ER, Thanabalasingham G, Szopa M, Shields BM, et al. Lipoprotein composition in HNF1A-MODY: differentiating between HNF1A-MODY and type 2 diabetes. Clin Chim Acta Int J Clin Chem. 2012;413:927–32.CrossRef
18.
go back to reference Thanabalasingham G, Shah N, Vaxillaire M, Hansen T, Tuomi T, Gašperíková D, et al. A large multi-centre european study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes. Diabetologia. 2011;54:2801–10.CrossRefPubMed Thanabalasingham G, Shah N, Vaxillaire M, Hansen T, Tuomi T, Gašperíková D, et al. A large multi-centre european study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes. Diabetologia. 2011;54:2801–10.CrossRefPubMed
19.
go back to reference Owen KR, Thanabalasingham G, James TJ, Karpe F, Farmer AJ, McCarthy MI, et al. Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations. Diabetes Care. 2010;33:1919–24.CrossRefPubMedPubMedCentral Owen KR, Thanabalasingham G, James TJ, Karpe F, Farmer AJ, McCarthy MI, et al. Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations. Diabetes Care. 2010;33:1919–24.CrossRefPubMedPubMedCentral
20.
go back to reference McDonald TJ, Colclough K, Brown R, Shields B, Shepherd M, Bingley P, et al. Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from type 1 diabetes. Diabet Med J Br Diabet Assoc. 2011;28:1028–33.CrossRef McDonald TJ, Colclough K, Brown R, Shields B, Shepherd M, Bingley P, et al. Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from type 1 diabetes. Diabet Med J Br Diabet Assoc. 2011;28:1028–33.CrossRef
21.
go back to reference Jeannot E, Mellottee L, Bioulac-Sage P, Balabaud C, Scoazec J-Y, Van Tran J, et al. Spectrum of HNF1A somatic mutations in hepatocellular adenoma differs from that in patients with MODY3 and suggests genotoxic damage. Diabetes. 2010;59:1836–44.CrossRefPubMedPubMedCentral Jeannot E, Mellottee L, Bioulac-Sage P, Balabaud C, Scoazec J-Y, Van Tran J, et al. Spectrum of HNF1A somatic mutations in hepatocellular adenoma differs from that in patients with MODY3 and suggests genotoxic damage. Diabetes. 2010;59:1836–44.CrossRefPubMedPubMedCentral
22.
go back to reference Baltacı OF, Çolakoğlu Ş, Güllü Amuran G, Aydın N, Sarğın M, Karabay A, et al. Exploring the role of miRNAs in the diagnosis of MODY3. Turk J Med Sci. 2018;48:620–7.PubMed Baltacı OF, Çolakoğlu Ş, Güllü Amuran G, Aydın N, Sarğın M, Karabay A, et al. Exploring the role of miRNAs in the diagnosis of MODY3. Turk J Med Sci. 2018;48:620–7.PubMed
23.
go back to reference Østoft SH, Bagger JI, Hansen T, Pedersen O, Faber J, Holst JJ, et al. Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial. Diabetes Care. 2014;37:1797–805.CrossRefPubMed Østoft SH, Bagger JI, Hansen T, Pedersen O, Faber J, Holst JJ, et al. Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial. Diabetes Care. 2014;37:1797–805.CrossRefPubMed
24.
go back to reference Christensen AS, Hædersdal S, Støy J, Storgaard H, Kampmann U, Forman JL, et al. Efficacy and safety of Glimepiride with or without Linagliptin treatment in patients with HNF1A diabetes (maturity-Onset diabetes of the Young Type 3): a Randomized, Double-Blinded, Placebo-Controlled, crossover trial (GLIMLINA). Diabetes Care. 2020;43:2025–33.CrossRefPubMedPubMedCentral Christensen AS, Hædersdal S, Støy J, Storgaard H, Kampmann U, Forman JL, et al. Efficacy and safety of Glimepiride with or without Linagliptin treatment in patients with HNF1A diabetes (maturity-Onset diabetes of the Young Type 3): a Randomized, Double-Blinded, Placebo-Controlled, crossover trial (GLIMLINA). Diabetes Care. 2020;43:2025–33.CrossRefPubMedPubMedCentral
25.
go back to reference Urakami T, Habu M, Okuno M, Suzuki J, Takahashi S, Yorifuji T. Three years of liraglutide treatment offers continuously optimal glycemic control in a pediatric patient with maturity-onset diabetes of the young type 3. J Pediatr Endocrinol Metab JPEM. 2015;28:327–31.PubMed Urakami T, Habu M, Okuno M, Suzuki J, Takahashi S, Yorifuji T. Three years of liraglutide treatment offers continuously optimal glycemic control in a pediatric patient with maturity-onset diabetes of the young type 3. J Pediatr Endocrinol Metab JPEM. 2015;28:327–31.PubMed
26.
go back to reference Docena MK, Faiman C, Stanley CM, Pantalone KM. Mody-3: novel HNF1A mutation and the utility of glucagon-like peptide (GLP)-1 receptor agonist therapy. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2014;20:107–11. Docena MK, Faiman C, Stanley CM, Pantalone KM. Mody-3: novel HNF1A mutation and the utility of glucagon-like peptide (GLP)-1 receptor agonist therapy. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2014;20:107–11.
27.
go back to reference Tuomi T, Honkanen EH, Isomaa B, Sarelin L, Groop LC. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3. Diabetes Care. 2006;29:189–94.CrossRefPubMed Tuomi T, Honkanen EH, Isomaa B, Sarelin L, Groop LC. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3. Diabetes Care. 2006;29:189–94.CrossRefPubMed
28.
go back to reference Lumb AN, Gallen IW. Treatment of HNF1-alpha MODY with the DPP-4 inhibitor sitagliptin(1). Diabet Med J Br Diabet Assoc. 2009;26:189–90.CrossRef Lumb AN, Gallen IW. Treatment of HNF1-alpha MODY with the DPP-4 inhibitor sitagliptin(1). Diabet Med J Br Diabet Assoc. 2009;26:189–90.CrossRef
29.
go back to reference B K. T K, J S, M S, N N, M B, Dipeptidyl peptidase-IV inhibitors are efficient adjunct therapy in HNF1A maturity-onset diabetes of the young patients-report of two cases. Diabetes Technol Ther. 2010;12.313–6 B K. T K, J S, M S, N N, M B, Dipeptidyl peptidase-IV inhibitors are efficient adjunct therapy in HNF1A maturity-onset diabetes of the young patients-report of two cases. Diabetes Technol Ther. 2010;12.313–6
Metadata
Title
De novo HNF1A mutation of young maturity-onset diabetes 3 of a young girl—Case report
Authors
Haoran Peng
Jianbo Li
Zhang Wang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2023
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-023-01293-7

Other articles of this Issue 1/2023

BMC Endocrine Disorders 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.